Free Access
Med Sci (Paris)
Volume 29, Number 4, Avril 2013
Page(s) 373 - 382
Section M/S Revues
Published online 26 April 2013
  1. UNAIDS. World AIDS Day report, 2011. [Google Scholar]
  2. Montaner JS. Treatment as prevention: a double hat-trick. Lancet 2011 ; 378 : 208–209. [CrossRef] [PubMed] [Google Scholar]
  3. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011 ; 378 : e23–e25. [CrossRef] [PubMed] [Google Scholar]
  4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 ; 365 : 493–505. [Google Scholar]
  5. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001 ; 357 : 1149–1153. [CrossRef] [PubMed] [Google Scholar]
  6. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000 ; 342 : 921–929. [Google Scholar]
  7. European collaborative study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 ; 40 : 458–465. [CrossRef] [PubMed] [Google Scholar]
  8. Lallemant M, Jourdain G, Le Coeur S, et al. Prévention de la transmission mère-enfant du VIH : un protocole simple, d’une efficacité remarquable. Med Sci (Paris) 2005 ; 21 : 28–29. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012 ; 379 : 221–228. [CrossRef] [PubMed] [Google Scholar]
  10. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment, heterosexual transmission of HIV-1: cross sectional, prospective cohort study. Br Med J 2010 ; 340 : c2205. [CrossRef] [PubMed] [Google Scholar]
  11. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010 ; 375 : 2092–2098. [CrossRef] [PubMed] [Google Scholar]
  12. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008 ; 35 : 912–915. [CrossRef] [PubMed] [Google Scholar]
  13. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011 ; 25 : 473–477. [CrossRef] [PubMed] [Google Scholar]
  14. Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010 ; 55 : 232–238. [CrossRef] [PubMed] [Google Scholar]
  15. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian study group on HIV heterosexual transmission. Arch Intern Med 1994; 154 : 1971–1976. [CrossRef] [PubMed] [Google Scholar]
  16. Sullivan P, Kayitenkore K, Chomba E, et al. Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia. In : 5th International AIDS Society Conference on HIV pathogenesis, Treatment and prevention, July 19–22, 2009. Cape Town, South Africa, 2009 (abstract WEAC101). [Google Scholar]
  17. Anglemyer A, Rutherford GW, Baggaley RC, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011 : CD009153. [Google Scholar]
  18. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 ; 365 : 493–505. [Google Scholar]
  19. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010 ; 5 : e11068. [CrossRef] [PubMed] [Google Scholar]
  20. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010 ; 376 : 532–539. [CrossRef] [PubMed] [Google Scholar]
  21. Cazein F, Lot F, Pillonel J, et al. Surveillance de l’infection à VIH-sida en France, 2009. BEH 2010 ; 45–46 : 467–472. [Google Scholar]
  22. Law MG, Woolley I, Templeton DJ, et al. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc 2011 ; 14 : 10. [CrossRef] [PubMed] [Google Scholar]
  23. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009 ; 373 : 48–57. [CrossRef] [PubMed] [Google Scholar]
  24. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000 ; 287 : 650–654. [CrossRef] [PubMed] [Google Scholar]
  25. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. Aids 2001 ; 15 : 1287–1294. [CrossRef] [PubMed] [Google Scholar]
  26. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011 ; 378 : 256–268. [CrossRef] [PubMed] [Google Scholar]
  27. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006 ; 3 : e124. [CrossRef] [PubMed] [Google Scholar]
  28. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010 ; 5 : 277–282. [CrossRef] [PubMed] [Google Scholar]
  29. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010 ; 51 : 392–400. [CrossRef] [PubMed] [Google Scholar]
  30. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009 ; 373 : 1352–1363. [CrossRef] [PubMed] [Google Scholar]
  31. Supervie V., The hidden HIV epidemic: what do mathematical models tell us? In : XIXth International AIDS Conference, July 22–27, 2012; Washington DC Etats-Unis 2012. [Google Scholar]
  32. Yéni P. (sous la direction de). Rapport d’experts Prise en charge médicale des personnes infectées par le VIH. Paris : La Documentation Française, 2010. [Google Scholar]
  33. FHDH. Retour d’informations clinico-épidémiologiques (RICE), 2010. [Google Scholar]
  34. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 ; 329 : 1168–1174. [CrossRef] [PubMed] [Google Scholar]
  35. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 ; 363 : 2587–2599. [CrossRef] [PubMed] [Google Scholar]
  36. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012 ; 367 : 423–434. [CrossRef] [PubMed] [Google Scholar]
  37. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 ; 367 : 399–410. [CrossRef] [PubMed] [Google Scholar]
  38. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 2011 ; 58 : e51–e52. [CrossRef] [PubMed] [Google Scholar]
  39. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 2010 ; 107 : 12381–12386. [Google Scholar]
  40. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009 ; 48 : 806–815. [CrossRef] [PubMed] [Google Scholar]
  41. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008 ; 22 : 1829–1839. [CrossRef] [PubMed] [Google Scholar]
  42. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa, India: a simulation study. PLoS One 2008 ; 3 : e2077. [CrossRef] [PubMed] [Google Scholar]
  43. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP), its impact on HIV-1 transmission in South Africa. PLoS One 2010 ; 5 : e13646. [CrossRef] [PubMed] [Google Scholar]
  44. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence, spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One 2011 ; 6 : e18165. [CrossRef] [PubMed] [Google Scholar]
  45. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007 ; 2 : e875. [Google Scholar]
  46. Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions, treatment programs: predicting HIV transmission, resistance. Sci Rep, 2011 ; 1 : 185. [CrossRef] [PubMed] [Google Scholar]
  47. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2 : 14ra4. [CrossRef] [PubMed] [Google Scholar]
  48. Legeai C, Auvert B. La circoncision : un espoir de réduction de l’infection à VIH en Afrique australe. Med Sci (Paris) 2008 ; 24 : 499–504. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  49. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 ; 361 : 2209–2220. [CrossRef] [PubMed] [Google Scholar]
  50. Jarzebowski W, Caumes E, Dupin N, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med 2012 ; 172 : 1237–1243. [CrossRef] [PubMed] [Google Scholar]
  51. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral Tenofovir, oral Tenofovir/Emtricitabine, or vaginal Tenofovir gel in the Voice study (MTN 003). 20th Conference on retroviruses and opportunistic infections. Atlanta, USA: March 2013,Abstract n° 26LB. [Google Scholar]
  52. Blanche S, Warszawski J. Tolérance pour l’enfant des antirétroviraux durant la grossesse. Med Sci (Paris) 2013 ; 29 : 383–388. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  53. Supervie V, Costagliola D. The spectrum of engagement in HIV care in France: strengths and gaps. 20th Conference on retroviruses and opportunistic infections. Atlanta, USA: March 2013, Abstract n° 1030 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.